Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 6:14:225.
doi: 10.1186/s12888-014-0225-8.

Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study

Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study

Antoni Sicras-Mainar et al. BMC Psychiatry. .

Abstract

Background: To evaluate the prevalence and impact of negative symptoms on healthcare resources utilization and costs in patients with schizophrenia.

Methods: A retrospective study was conducted using electronic medical records from the health provider BSA (Badalona, Spain). All adult outpatients with a diagnosis of schizophrenia were followed for 12 months. Two study groups were defined by the presence or absence of negative symptoms based on the PANSS Negative Symptoms Factor (N1-N4, N6, G7 and G16). Healthcare (direct cost) and non-healthcare costs (work productivity losses) were described. An ANCOVA model was used for correction, p < 0.05.

Results: One thousand one hundred and twenty patients were included in the study (mean age: 46.8 ± 13.8 years; male: 58.4%). One or more negative symptoms were present in 52.5% of patients (95% CI: 49.6-55.4%). The most frequent were passive/apathetic social withdrawal and emotional withdrawal (60.5% and 49.8%, respectively). Patients with negative symptoms showed a greater mean number of comorbid conditions and pharmacological treatments. The adjusted unit healthcare cost related to the presence/absence of negative symptoms was €2,190.80 and €1,787.60 and the healthcare cost was €2,085.00 and €1,659.10, respectively; (p < 0.001). Patients with negative symptoms used more healthcare resources, mainly derived from primary care. The presence of negative symptoms was associated with being male, dyslipidemia, obesity and arterial hypertension (OR = 1.7, 1.4, 1.4 and 1.2, respectively).

Conclusions: Negative symptoms are highly prevalent in adult outpatients with schizophrenia with a relevant economic impact on the healthcare system.

PubMed Disclaimer

Figures

Figure 1
Figure 1
General study disposition. Follow-up for all patients was 1 year after inclusion. *Patients were excluded for the following: missing or inconsistent data (N = 33; 17.8%), loss to follow-up (N = 45; 24.3%), moved to other areas (N = 37; 20.0%) and other reasons (N = 70; 37.9%). NS: negative symptoms.

References

    1. Torres-González F, Ibanez-Casas I, Saldivia S, Ballester D, Grandón P, Moreno-Küstner B, Xavier M, Gómez-Beneyto M. Unmet needs in the management of schizophrenia. Neuropsychiatr Dis Treat. 2014;10:97–110. doi: 10.2147/NDT.S41063. - DOI - PMC - PubMed
    1. Saha S, Chant D, McGrath J. Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. Int J Methods Psychiatr Res. 2008;17:55–61. doi: 10.1002/mpr.240. - DOI - PMC - PubMed
    1. García-Portilla MP, Bobes J. The new challenge in identifying the negative syndrome of schizophrenia. Rev Psiquiatr Salud Ment. 2013;6:141–143. doi: 10.1016/j.rpsm.2013.09.002. - DOI - PubMed
    1. Bobes J, Arango C, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group: prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71:280–286. doi: 10.4088/JCP.08m04250yel. - DOI - PubMed
    1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692. doi: 10.1016/j.euroneuro.2014.03.008. - DOI - PubMed

Publication types